Welcome to the Urologic Cancer Innovation Lab at Stanford
The Urologic Cancer Innovation Lab (UCIL) is directed by Geoffrey Sonn, M.D., and is part of the Department of Urology and Radiology in the Stanford School of Medicine. We are affiliated with the Stanford Cancer Institute, Bio-X, and the Center for Artificial Intelligence in Medicine & Imaging (AIMI).
Our mission is to develop cutting-edge technologies and rapidly translate them into clinical use to improve diagnosis and treatment of urologic cancers. To accomplish our mission, we leverage the interdisciplinary excellence at Stanford in medicine, engineering, and computer science. To facilitate clinical translation, we collaborate with industry partners by helping to optimize and clinically test new diagnostic tests and treatments.
- See our presentations at the 2021 AUA Meeting
- Congratulations Dr. Sonn! Geoff Sonn's project titled Early Detection of Prostate Cancer Progression in Active Surveillance has been awarded by the Cancer Research UK International Alliance for Cancer Early Detection (ACED) in collaboration with University College London.
If you are interested in supporting the work of the UCIL, please contact Evelyn Klass-Rodewald, Medical Center Development, at email@example.com